110 results
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
17 Apr 24
Departure of Directors or Certain Officers
4:23pm
relationship between Client and Consultant. Consultant is not authorized to make any representation, contract or commitment on behalf of the Company
424B3
szowodbhkqcoawd5
16 Feb 24
Prospectus supplement
4:31pm
8-K
EX-99.1
aaasvv
16 Feb 24
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
4:03pm
8-K
EX-10.2
7gg rfpbx8sphypf5
1 Nov 23
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
4:21pm
8-K
EX-99.1
don3 tuaeilb5hyzf
27 Sep 23
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024
8:45am
424B5
c6yy7huem
14 Aug 23
Prospectus supplement for primary offering
8:00am
8-K
EX-10.1
9ai17mann1awwxr c2
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
8-K
bnyh7uq trqjrcw6tip
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
8-K
EX-10.2
6zqzzu
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
8-K
EX-99.1
4op8f iy6
6 Dec 22
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
6:37am
8-K
EX-99.1
tyfswf
7 Nov 22
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
4:16pm